In the context of investigating gastric cancer drug resistance, research has demonstrated that the upregulation of the KEAP1/NRF2 signaling pathway significantly diminishes the sensitivity of gastric cancer cells to fluorouracil (5-FU) and oxaliplatin (Zhou et al., 2023). This evidence concerns the gene KEAP1 and gastric cancer.